Navigation Links
Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-SMN Rx Data Presented at 2013 AAN Annual Meeting
Date:3/14/2013

CARLSBAD, Calif., March 14, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host an investor event and a live webcast on Thursday, March 21, 2013 at 7:30 a.m. Pacific Time to discuss the ISIS-SMNRx Phase 1 data presented at the 2013 American Academy of Neurology Annual Meeting.

Interested parties may register to attend the event in San Diego, CA, or access the webcast on the "Investors & Media" page at www.isispharm.com.  The webcast will remain posted on Isis' Web site for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets, including Europe.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis' strategic alliance with Biogen Idec, and the discovery, development, activity, therapeutic and commercial potential and safety of ISIS-SMNRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, which is on file with the SEC. Copies of this and other documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sagent Pharmaceuticals Selects ProspectoRx and Clinical Pharmacology
2. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
3. Salix Pharmaceuticals Commits $1.125M to AGA Research Foundation
4. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
5. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
6. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
7. Isis Pharmaceuticals Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx
8. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
9. N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
10. Inovio Pharmaceuticals Closes $15.1 Million Offering of Common Stock and Warrants
11. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... India , March 23, 2017 ... growing ageing population, increasing diabetic population, accelerating economic growth and ... of this industry are higher life expectancy of ESRD patients, ... in emerging markets. However, the expansion of the market is ... ...
(Date:3/23/2017)... and INDIANAPOLIS , March ... LLY ) and the William Sansum Diabetes Center ... of Latino people affected by diabetes through enhanced research, ... of diabetes and cardiovascular disease bears a disproportionate weight ... ," said David Kerr , M.D., FRCPE, ...
(Date:3/23/2017)... , March 23, 2017   BioSpace , ... resource, has partnered with Indiana Biosciences Research Institute ... organizations and educational institutions to bring the state,s ... first-ever BioIndiana Hotbed map, an artistic representation of the ... was presented to Vice President Mike Pence , ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the ... teacher preparation programs. The NCTQ report suggests, based on a review of GPA and ... improve teacher quality in the U.S. It argues that this higher bar should be ...
(Date:3/23/2017)... ... , ... The IoT (Internet of Things) is revolutionizing the way the world ... businesses and individual consumers alike. Laboratories can maximize their profit margin by increasing ... $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT ...
(Date:3/23/2017)... ... March 23, 2017 , ... Benefits ... an innovative mobile app and centralized benefits dashboard solving one of the top ... from multiple locations. For the first time, employees can access up-to-date information and ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... businesses of the greater Fort Collins area, has unveiled a collaboration with nonprofit ... involvement program. Donations to this worthy cause may now be made at ...
(Date:3/23/2017)... ... March 23, 2017 , ... ChenMed, a privately owned ... of the strategic executive team expansion needed to further optimize growth and performance. ... team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler and ...
Breaking Medicine News(10 mins):